OBJECTIVE: To determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer compared with new users of histamine-2 receptor antagonists (H2RAs).
DESIGN: Using the UK Clinical Practice Research Datalink, we conducted a population-based cohort study using a new-user active comparator design. From 1 January 1990 to 30 April 2018, we identified 973 281 new users of PPIs and 193 306 new users of H2RAs. Cox proportional hazards models were fit to estimate HRs and 95% CIs of gastric cancer, and the number needed to harm was estimated using the Kaplan-Meier method. The models were weighted using standardised mortality ratio weights using calendar time-specific propensity scores. Secondary analyses assessed duration and dose-response associations.
RESULTS: After a median follow-up of 5.0 years, the use of PPIs was associated with a 45% increased risk of gastric cancer compared with the use of H2RAs (HR 1.45, 95% CI 1.06 to 1.98). The number needed to harm was 2121 and 1191 for five and 10 years after treatment initiation, respectively. The HRs increased with cumulative duration, cumulative omeprazole equivalents and time since treatment initiation. The results were consistent across several sensitivity analyses.
CONCLUSION: The findings of this large population-based cohort study indicate that the use of PPIs is associated with an increased risk of gastric cancer compared with the use of H2RAs, although the absolute risk remains low.
|組織名||Epidemiology, Biostatistics, and Occupational Health, McGill University,;Montreal, Quebec, Canada.;Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research,;Division of General Internal Medicine, Department of Medicine, McGill University;Health Centre, Montreal, Quebec, Canada.;Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada.;Faculty of Pharmacy and the Department of Social and Preventive Medicine,;Universite de Montreal, Montreal, Quebec, Canada.;Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada.;Department of Medicine, McGill University, Montreal, Quebec, Canada.;Montreal, Quebec, Canada firstname.lastname@example.org.;Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec,;Canada.|